Comparison of outcomes after plasma therapy or eculizumab in pediatric patients with atypical hemolytic uremic syndrome

[1]  S. Ito,et al.  Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan , 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  OUP accepted manuscript , 2022, Nephrology Dialysis Transplantation.

[3]  G. Ardissino,et al.  Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality , 2021, Kidney international reports.

[4]  H. Haller,et al.  Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis , 2019, British journal of haematology.

[5]  M. Nangaku,et al.  Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance , 2018, Clinical and Experimental Nephrology.

[6]  M. Nangaku,et al.  Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance , 2018, Clinical and Experimental Nephrology.

[7]  K. Iijima,et al.  Clinical features in a series of 258 Japanese pediatric patients with thrombotic microangiopathy , 2018, Clinical and Experimental Nephrology.

[8]  O. Uemura,et al.  Creatinine-based estimated glomerular filtration rate for children younger than 2 years , 2018, Clinical and Experimental Nephrology.

[9]  J. Macneil,et al.  High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine , 2017, MMWR. Morbidity and mortality weekly report.

[10]  G. Ardissino,et al.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2017, Kidney international.

[11]  V. Afshar-Kharghan.  Atypical hemolytic uremic syndrome. , 2016, Hematology. American Society of Hematology. Education Program.

[12]  M. Nangaku,et al.  Clinical guides for atypical hemolytic uremic syndrome in Japan , 2016, Clinical and Experimental Nephrology.

[13]  P. Ruggenenti,et al.  Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  G. Ardissino,et al.  Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. , 2016, Kidney international.

[15]  R. Brodsky.  Complement in hemolytic anemia. , 2015, Blood.

[16]  G. Remuzzi,et al.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies , 2015, Kidney international.

[17]  R. Coppo,et al.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children , 2015, Pediatric Nephrology.

[18]  G. Ariceta,et al.  An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome , 2014, Pediatric Nephrology.

[19]  S. Ito,et al.  Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease , 2014, Clinical and Experimental Nephrology.

[20]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[21]  L. Rostaing,et al.  Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[22]  S. Ito,et al.  Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study , 2011, Clinical and Experimental Nephrology.

[23]  G. Remuzzi,et al.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[24]  G. Ariceta,et al.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome , 2009, Pediatric nephrology (Berlin, West).

[25]  H. Tiddens,et al.  Haemolytic uraemic syndrome. , 1979, Paediatrician.